Company Overview: Myomo

About the Company

Myomo
Facebook Tweeter Linkedin

Patented EMG (electromyography) control software continuously monitors and senses, but does not stimulate, the affected muscles. The user self initiates and achieves natural movement patterns by their own muscular signals that indicate intention to move. The system senses even a very weak EMG muscle signal and then processes data to a motor on the device that enables desired motion. This processing occurs so quickly that it is not apparent to the patient. Importantly, the EMG-driven device requires that users are actively engaged throughout the movement; if they stop, the device stops. No electrical stimulation or invasive procedures are employed.

By supporting the research into Myoelectric technology in 1990†, the Veterans Administration promoted and inspired development for a future myoelectric orthosis that could be of benefit to Veterans that have upper extremity impairment. Today, Myomo is assisting Veterans with MyoPro.


Investor Toolkit

Company News

  • Myomo, Inc. Reports Third Quarter 2017 Results

    CAMBRIDGE, Mass.–(BUSINESS WIRE)– Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today reports its financial results for the three and nine months ended September 30, 2017. Highlights and Achievements in the Third...

  • Myomo, Inc. Issues November 2017 Shareholder Letter

    CAMBRIDGE, Mass.–(BUSINESS WIRE)– Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today issued a letter to shareholders to give an update on third quarter 2017 and ongoing MyoPro® commercial activities. An accompanying...

  • Myomo Enters Canadian Market

    CAMBRIDGE, Mass.–(BUSINESS WIRE)– Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that its Application for a Canadian Medical Device License has been approved by Health Canada. With the license, Myomo...

  • Myomo, Inc. to Report Third Quarter 2017 Results on November 6, 2017

    CAMBRIDGE, Mass.–(BUSINESS WIRE)– Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will release its unaudited financial results for the quarter ended September 30, 2017 on Monday, November 6,...

Email Subscription

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address